A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies

Conditions:   Cervical Cancer;   Microsatellite Instability (MSI)-High Endometrial Cancer;   Gastric Cancer (Including Stomach and Gastroesophageal Junction [GEJ]);   Esophageal Cancer;   Hepatocellular Carcinoma;   Melanoma (Uveal Melanoma Excluded);   Merkel Cell Carcinoma;   Mesothelioma;   MSI-high Colorectal Cancer;   Non-small Cell Lung Cancer (NSCLC);   Ovarian Cancer;   Squamous Cell Carcinoma of the Head and Neck (SCCHN);   Small Cell Lung Cancer (SCLC);   Renal Cell Carcinoma (RCC);   Triple-negative Breast Cancer;   Urothelial Carcinoma;   Diffuse Large B-cell Lymphoma
Intervention:   Biological: INCAGN02385
Sponsor:   Incyte Biosciences International Sàrl
Not yet recruiting

https://ift.tt/2xfjlHu